お知らせ
お知らせ
Jitsubo CO., LTD. announced the signing of an exclusive manufacturing license agreement with Novo Nordisk A/S(2880 Bagsvaerd, Denmark, hereinafter “Novo Nordisk”)for Novo Nordisk to use and have manufacturing rights to Jitsubo’s proprietary peptide manufacturing technology, Molecular HivingTM, for synthesis of peptides in the field of obesity, diabetes, and the related therapeutic areas.